Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients : week-192 overall and subgroup analyses from STARTMRK
Voir/ Ouvrir
Date
2012Auteur(s) d'entreprise
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Grupo de Investigación en Enfermedades Infecciosas HUSI - PUJ
Type
Artículo de revista
ISSN
1528-4336 / 1945-5771 (Electrónico)
Des pages
228-232
Type d'élément
Reporte de caso
Partager cet enregistrement
Citación
Metadata
Afficher la notice complète
Documents PDF
Abstrait
We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV- infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads.
Lien vers la ressource
https://www-tandfonline-com.ezproxy.javeriana.edu.co/doi/abs/10.1310/hct1304-228Origine
HIV Clinical Trials; Vol. 13 Núm. 4 (2012)
Google Analytics Statistics
Collections
- Artículos [164]